These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 3097254)

  • 1. (-)Deprenyl in perspective: prophylaxis for Parkinson's disease?
    Sandler M
    J Neural Transm Suppl; 1986; 22():107-15. PubMed ID: 3097254
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Selegiline and the prophylaxis of Parkinson's disease.
    Sandler M; Willoughby J; Glover V; Gibb C
    J Neural Transm Suppl; 1987; 25():35-43. PubMed ID: 3123604
    [TBL] [Abstract][Full Text] [Related]  

  • 3. R-(-)-deprenyl as a possible protective agent in Parkinson's disease.
    Tetrud JW; Langston JW
    J Neural Transm Suppl; 1987; 25():69-79. PubMed ID: 3123606
    [TBL] [Abstract][Full Text] [Related]  

  • 4. R-(-)-deprenyl and parkinsonism.
    Yahr MD
    J Neural Transm Suppl; 1987; 25():5-12. PubMed ID: 3123605
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Medicamentous strategy for improving the quality of life in the senescence].
    Knoll J
    Wien Med Wochenschr Suppl; 1986; 98():1-18. PubMed ID: 3097965
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacology of MAO B inhibitors: mode of action of (-)deprenyl in Parkinson's disease.
    Youdim MB
    J Neural Transm Suppl; 1986; 22():91-105. PubMed ID: 3097263
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of deprenyl (selegiline) on the natural history of Parkinson's disease.
    Tetrud JW; Langston JW
    Science; 1989 Aug; 245(4917):519-22. PubMed ID: 2502843
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of MAO in MPTP toxicity--a review.
    Glover V; Gibb C; Sandler M
    J Neural Transm Suppl; 1986; 20():65-76. PubMed ID: 3091762
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of MAO-b inhibitors in the treatment of Parkinson's disease.
    Ruggieri S; Stocchi F; Denaro A; Baronti F; Agnoli A
    J Neural Transm Suppl; 1986; 22():227-33. PubMed ID: 3097257
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of fluorinated 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine analogs with potent nigrostriatal toxicity for potential use in positron emission tomography studies.
    Harik SI; Riachi NJ; Hritz MA; Berridge MS; Sayre LM
    J Pharmacol Exp Ther; 1993 Aug; 266(2):790-5. PubMed ID: 8355208
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MAO type B inhibitors as adjunct to L-dopa therapy.
    Youdim MB; Finberg JP
    Adv Neurol; 1987; 45():127-36. PubMed ID: 3103383
    [No Abstract]   [Full Text] [Related]  

  • 12. D-deprenyl protects nigrostriatal neurons against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced dopaminergic neurotoxicity.
    Muralikrishnan D; Samantaray S; Mohanakumar KP
    Synapse; 2003 Oct; 50(1):7-13. PubMed ID: 12872288
    [TBL] [Abstract][Full Text] [Related]  

  • 13. (-)-Deprenyl, a selective MAO-B inhibitor, with apoptotic and anti-apoptotic properties.
    Magyar K; Szende B
    Neurotoxicology; 2004 Jan; 25(1-2):233-42. PubMed ID: 14697898
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The pharmacology of (-)deprenyl.
    Knoll J
    J Neural Transm Suppl; 1986; 22():75-89. PubMed ID: 3097262
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Toxins and Parkinson's disease: MPTP parkinsonism in humans and animals.
    Kopin IJ
    Adv Neurol; 1987; 45():137-44. PubMed ID: 3493621
    [No Abstract]   [Full Text] [Related]  

  • 16. Monoamine oxidase-B, monoamine oxidase-B inhibitors, and Parkinson's disease. A role for superoxide dismutase?
    Sandler M; Glover V; Clow A; Jarman J
    Adv Neurol; 1993; 60():238-41. PubMed ID: 8420141
    [No Abstract]   [Full Text] [Related]  

  • 17. MAO-B-Inhibitor selegiline (R-(-)-deprenyl). A new therapeutic concept in the treatment of Parkinson's disease. Proceedings of the international symposium. Berlin, January 23-25, 1987.
    J Neural Transm Suppl; 1987; 25():1-197. PubMed ID: 3123595
    [No Abstract]   [Full Text] [Related]  

  • 18. R-(-)-deprenyl as an adjuvant to levodopa in the treatment of Parkinson's disease.
    Rinne UK
    J Neural Transm Suppl; 1987; 25():149-55. PubMed ID: 3123601
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [History of deprenyl--the first selective inhibitor of monoamine oxidase type B].
    Knoll J
    Vopr Med Khim; 1997; 43(6):482-93. PubMed ID: 9503565
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Deprenyl in the treatment of Parkinson's disease. A specific type B monoamine oxidase inhibitor.
    Lieberman AN; Gopinathan G; Neophytides A; Hiesiger E; Nelson J; Walker R; Goodgold A
    N Y State J Med; 1984 Jan; 84(1):13-6. PubMed ID: 6422358
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.